Study Status: ACTIVE_NOT_RECRUITING
Recruit Status: ACTIVE_NOT_RECRUITING
Study Type: INTERVENTIONAL
Official Title: Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients
Brief Summary: Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating disease of the central nervous system.
Typical brain lesions of the disease may be partially repaired by an endogenous remyelination process which is limited and tends to deplete over the course of the disease.
Cladribine tablets are an approved treatment that promotes selective lymphocyte depletion, reducing the inflammatory activity of the disease.
The present study is based on the hypothesis that improved inflammatory control through cladribine tablets provides a tissue microenvironment more favorable for remyelination of brain lesions in MS.
This hypothesis will be evaluated by a single-arm, open-label, phase IV, single-center, proof-of-concept clinical trial in which 10 participants with relapsing-remitting, highly active MS, relatively early in the course of the disease, will receive conventional treatment with cladribine tablets and will be followed-up for 48 months.
Neurological, neuropsychological and magnetic resonance imaging (MRI) parameters will be measured.
Remyelination will be assessed by a novel MRI technique called the q-Space myelin map.
Additionally, the peripheral blood lymphocyte and cytokine profiles will be evaluated in order to understand the immunological aspects that influence the remyelination capacity in patients treated with cladribine tablets.
The study will be conducted in accordance with current regulations governing clinical research in Brazil.